Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Dec 15;98(12):2706–2713. doi: 10.1172/JCI119095

Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study.

R H Böger 1, C Skamira 1, S M Bode-Böger 1, G Brabant 1, A von zur Muhlen 1, J C Frolich 1
PMCID: PMC507734  PMID: 8981915

Abstract

We studied the effects of recombinant growth hormone on systemic nitric oxide (NO) formation and hemodynamics in a double-blind, placebo-controlled trial in adult patients with acquired growth hormone deficiency. 30 patients were randomly allocated to either recombinant human growth hormone (r-hGH; 2.0 IU/d) or placebo for 12 mo. In the subsequent 12 mo, the study was continued with both groups of patients receiving r-hGH. In months 1, 3, 6, 9, and 12 of each year, urine and plasma samples were collected for the determination of urinary nitrate and cyclic GMP as indices of systemic NO production, and of plasma IGF-1 levels. Cardiac output was measured in months 1, 12, and 24 by echocardiography. r-hGH induced a fourfold increase in plasma IGF-1 concentrations within the first month of treatment. Urinary nitrate and cyclic GMP excretion rates were low at baseline in growth hormone-deficient patients (nitrate, 96.8+/-7.4 micromol/mmol creatinine; cyclic GMP, 63.6+/-7.1 nmol/mmol creatinine) as compared with healthy controls (nitrate, 167.3+/-7.5 micromol/mmol creatinine; cyclic GMP, 155.2+/-6.9 nmol/mmol creatinine). These indices of NO production were significantly increased by r-hGH, within the first 12 mo in the GH group, and within the second 12 mo in the placebo group. While systolic and diastolic blood pressure were not significantly altered by r-hGH, cardiac output significantly increased by 30-40%, and total peripheral resistance decreased by approximately 30% in both groups when they were assigned to r-hGH treatment. In the second study year, when both groups were given r-hGH, there were no significant differences in plasma IGF-1, urinary nitrate, or cyclic GMP excretion, or hemodynamic parameters between both groups. In conclusion, systemic NO formation is decreased in untreated growth hormone-deficient patients. Treatment with recombinant human growth hormone normalizes urinary nitrate and cyclic GMP excretion, possibly via IGF-1 stimulation of endothelial NO formation, and concomitantly decreases peripheral arterial resistance. Increased NO formation may be one reason for improved cardiovascular performance of patients with acquired hypopituitarism during growth hormone therapy.

Full Text

The Full Text of this article is available as a PDF (204.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bar R. S., Boes M., Dake B. L., Booth B. A., Henley S. A., Sandra A. Insulin, insulin-like growth factors, and vascular endothelium. Am J Med. 1988 Nov 28;85(5A):59–70. doi: 10.1016/0002-9343(88)90398-1. [DOI] [PubMed] [Google Scholar]
  2. Bengtsson B. A., Edén S., Lönn L., Kvist H., Stokland A., Lindstedt G., Bosaeus I., Tölli J., Sjöström L., Isaksson O. G. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993 Feb;76(2):309–317. doi: 10.1210/jcem.76.2.8432773. [DOI] [PubMed] [Google Scholar]
  3. Blackett P. R., Weech P. K., McConathy W. J., Fesmire J. D. Growth hormone in the regulation of hyperlipidemia. Metabolism. 1982 Feb;31(2):117–120. doi: 10.1016/0026-0495(82)90121-4. [DOI] [PubMed] [Google Scholar]
  4. Blum W. F., Breier B. H. Radioimmunoassays for IGFs and IGFBPs. Growth Regul. 1994 Feb;4 (Suppl 1):11–19. [PubMed] [Google Scholar]
  5. Bode-Böger S. M., Böger R. H., Alfke H., Heinzel D., Tsikas D., Creutzig A., Alexander K., Frölich J. C. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation. 1996 Jan 1;93(1):85–90. doi: 10.1161/01.cir.93.1.85. [DOI] [PubMed] [Google Scholar]
  6. Bode-Böger S. M., Böger R. H., Creutzig A., Tsikas D., Gutzki F. M., Alexander K., Frölich J. C. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci (Lond) 1994 Sep;87(3):303–310. doi: 10.1042/cs0870303. [DOI] [PubMed] [Google Scholar]
  7. Boger R. H., Bode-Boger S. M., Gerecke U., Gutzki F. M., Tsikas D., Frolich J. C. Urinary NO3- excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-name in rats. Clin Exp Pharmacol Physiol. 1996 Jan;23(1):11–15. [PubMed] [Google Scholar]
  8. Böger R. H., Bode-Böger S. M., Gerecke U., Frölich J. C. Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulates urinary nitrate and cGMP excretion in rats. Cardiovasc Res. 1994 Apr;28(4):494–499. doi: 10.1093/cvr/28.4.494. [DOI] [PubMed] [Google Scholar]
  9. Böger R. H., Bode-Böger S. M., Mügge A., Kienke S., Brandes R., Dwenger A., Frölich J. C. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 1995 Oct;117(2):273–284. doi: 10.1016/0021-9150(95)05582-h. [DOI] [PubMed] [Google Scholar]
  10. Caidahl K., Edén S., Bengtsson B. A. Cardiovascular and renal effects of growth hormone. Clin Endocrinol (Oxf) 1994 Mar;40(3):393–400. doi: 10.1111/j.1365-2265.1994.tb03937.x. [DOI] [PubMed] [Google Scholar]
  11. Candipan R. C., Wang B. Y., Buitrago R., Tsao P. S., Cooke J. P. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):44–50. doi: 10.1161/01.atv.16.1.44. [DOI] [PubMed] [Google Scholar]
  12. Cooke J. P., Singer A. H., Tsao P., Zera P., Rowan R. A., Billingham M. E. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 1992 Sep;90(3):1168–1172. doi: 10.1172/JCI115937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cuneo R. C., Salomon F., Watts G. F., Hesp R., Sönksen P. H. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism. 1993 Dec;42(12):1519–1523. doi: 10.1016/0026-0495(93)90145-e. [DOI] [PubMed] [Google Scholar]
  14. Cuneo R. C., Salomon F., Wiles C. M., Hesp R., Sönksen P. H. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol (1985) 1991 Feb;70(2):688–694. doi: 10.1152/jappl.1991.70.2.688. [DOI] [PubMed] [Google Scholar]
  15. Daughaday W. H., Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989 Feb;10(1):68–91. doi: 10.1210/edrv-10-1-68. [DOI] [PubMed] [Google Scholar]
  16. Drexler H., Zeiher A. M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 1991 Dec 21;338(8782-8783):1546–1550. doi: 10.1016/0140-6736(91)92372-9. [DOI] [PubMed] [Google Scholar]
  17. Edén S., Wiklund O., Oscarsson J., Rosén T., Bengtsson B. A. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb. 1993 Feb;13(2):296–301. doi: 10.1161/01.atv.13.2.296. [DOI] [PubMed] [Google Scholar]
  18. Friedman M., Byers S. O., Rosenman R. H., Li C. H., Neuman R. Effect of subacute administration of human growth hormone on various serum lipid and hormone levels of hypercholesterolemic and normocholesterolemic subjects. Metabolism. 1974 Oct;23(10):905–912. doi: 10.1016/0026-0495(74)90039-0. [DOI] [PubMed] [Google Scholar]
  19. Haylor J., Singh I., el Nahas A. M. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int. 1991 Feb;39(2):333–335. doi: 10.1038/ki.1991.42. [DOI] [PubMed] [Google Scholar]
  20. Hoffman D. M., Crampton L., Sernia C., Nguyen T. V., Ho K. K. Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab. 1996 Mar;81(3):1123–1128. doi: 10.1210/jcem.81.3.8772586. [DOI] [PubMed] [Google Scholar]
  21. Juul A., Bang P., Hertel N. T., Main K., Dalgaard P., Jørgensen K., Müller J., Hall K., Skakkebaek N. E. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 1994 Mar;78(3):744–752. doi: 10.1210/jcem.78.3.8126152. [DOI] [PubMed] [Google Scholar]
  22. Jørgensen J. O., Pedersen S. A., Thuesen L., Jørgensen J., Ingemann-Hansen T., Skakkebaek N. E., Christiansen J. S. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1989 Jun 3;1(8649):1221–1225. doi: 10.1016/s0140-6736(89)92328-3. [DOI] [PubMed] [Google Scholar]
  23. Kanno K., Hirata Y., Emori T., Ohta K., Eguchi S., Imai T., Marumo F. L-arginine infusion induces hypotension and diuresis/natriuresis with concomitant increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin Exp Pharmacol Physiol. 1992 Sep;19(9):619–625. doi: 10.1111/j.1440-1681.1992.tb00514.x. [DOI] [PubMed] [Google Scholar]
  24. Krieg R. J., Jr, Santos F., Chan J. C. Growth hormone, insulin-like growth factor and the kidney. Kidney Int. 1995 Aug;48(2):321–336. doi: 10.1038/ki.1995.300. [DOI] [PubMed] [Google Scholar]
  25. Kubes P., Suzuki M., Granger D. N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4651–4655. doi: 10.1073/pnas.88.11.4651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Küng C. F., Lüscher T. F. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension. 1995 Feb;25(2):194–200. doi: 10.1161/01.hyp.25.2.194. [DOI] [PubMed] [Google Scholar]
  27. Landin-Wilhelmsen K., Wilhelmsen L., Lappas G., Rosén T., Lindstedt G., Lundberg P. A., Bengtsson B. A. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) 1994 Sep;41(3):351–357. doi: 10.1111/j.1365-2265.1994.tb02556.x. [DOI] [PubMed] [Google Scholar]
  28. Lapidus L., Bengtsson C., Larsson B., Pennert K., Rybo E., Sjöström L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed) 1984 Nov 10;289(6454):1257–1261. doi: 10.1136/bmj.289.6454.1257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Larsson B., Svärdsudd K., Welin L., Wilhelmsen L., Björntorp P., Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984 May 12;288(6428):1401–1404. doi: 10.1136/bmj.288.6428.1401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lehmann E. D., Hopkins K. D., Weissberger A. J., Gosling R. G., Sönksen P. H. Aortic distensibility in growth hormone deficient adults. Lancet. 1993 Jan 30;341(8840):309–309. doi: 10.1016/0140-6736(93)92664-f. [DOI] [PubMed] [Google Scholar]
  31. Ludbrook J. Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res. 1994 Mar;28(3):303–311. doi: 10.1093/cvr/28.3.303. [DOI] [PubMed] [Google Scholar]
  32. Markussis V., Beshyah S. A., Fisher C., Sharp P., Nicolaides A. N., Johnston D. G. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet. 1992 Nov 14;340(8829):1188–1192. doi: 10.1016/0140-6736(92)92892-j. [DOI] [PubMed] [Google Scholar]
  33. Merimee T. J., Hollander W., Fineberg S. E. Studies of hyperlipidemia in the HGH-deficient state. Metabolism. 1972 Nov;21(11):1053–1061. doi: 10.1016/0026-0495(72)90036-4. [DOI] [PubMed] [Google Scholar]
  34. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993 Dec 30;329(27):2002–2012. doi: 10.1056/NEJM199312303292706. [DOI] [PubMed] [Google Scholar]
  35. Motani A., Forster L., Tull S., Anggård E. E., Ferns G. A. Insulin-like growth factor-I modulates monocyte adhesion to EAhy 926 endothelial cells. Int J Exp Pathol. 1996 Feb;77(1):31–35. doi: 10.1046/j.1365-2613.1996.960098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Myers P. R., Wright T. F., Tanner M. A., Ostlund R. E., Jr The effects of native LDL and oxidized LDL on EDRF bioactivity and nitric oxide production in vascular endothelium. J Lab Clin Med. 1994 Nov;124(5):672–683. [PubMed] [Google Scholar]
  37. Mügge A., Brandes R. P., Böger R. H., Dwenger A., Bode-Böger S., Kienke S., Frölich J. C., Lichtlen P. R. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 1994 Dec;24(6):994–998. doi: 10.1097/00005344-199424060-00019. [DOI] [PubMed] [Google Scholar]
  38. Pohl U., Heydari N., Galle J. Effects of LDL on intracellular free calcium and nitric oxide-dependent cGMP formation in porcine endothelial cells. Atherosclerosis. 1995 Oct;117(2):169–178. doi: 10.1016/0021-9150(95)05570-m. [DOI] [PubMed] [Google Scholar]
  39. Radomski M. W., Salas E. Nitric oxide--biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis. 1995 Dec;118 (Suppl):S69–S80. [PubMed] [Google Scholar]
  40. Riedel M., Brabant G., Rieger K., von zur Mühlen A. Growth hormone therapy in adults: rationales, results, and perspectives. Exp Clin Endocrinol. 1994;102(4):273–283. doi: 10.1055/s-0029-1211292. [DOI] [PubMed] [Google Scholar]
  41. Rosén T., Bengtsson B. A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990 Aug 4;336(8710):285–288. doi: 10.1016/0140-6736(90)91812-o. [DOI] [PubMed] [Google Scholar]
  42. Rosén T., Edén S., Larson G., Wilhelmsen L., Bengtsson B. A. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993 Sep;129(3):195–200. doi: 10.1530/acta.0.1290195. [DOI] [PubMed] [Google Scholar]
  43. Rosén T., Johannsson G., Johansson J. O., Bengtsson B. A. Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. A review paper. Horm Res. 1995;43(1-3):93–99. doi: 10.1159/000184245. [DOI] [PubMed] [Google Scholar]
  44. Rudling M., Norstedt G., Olivecrona H., Reihnér E., Gustafsson J. A., Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6983–6987. doi: 10.1073/pnas.89.15.6983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Saccà L., Cittadini A., Fazio S. Growth hormone and the heart. Endocr Rev. 1994 Oct;15(5):555–573. doi: 10.1210/edrv-15-5-555. [DOI] [PubMed] [Google Scholar]
  46. Salomon F., Cuneo R. C., Hesp R., Sönksen P. H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989 Dec 28;321(26):1797–1803. doi: 10.1056/NEJM198912283212605. [DOI] [PubMed] [Google Scholar]
  47. Thuesen L., Christiansen J. S., Sørensen K. E., Jørgensen J. O., Orskov H., Henningsen P. Increased myocardial contractility following growth hormone administration in normal man. An echocardiographic study. Dan Med Bull. 1988 Apr;35(2):193–196. [PubMed] [Google Scholar]
  48. Tsao P. S., McEvoy L. M., Drexler H., Butcher E. C., Cooke J. P. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation. 1994 May;89(5):2176–2182. doi: 10.1161/01.cir.89.5.2176. [DOI] [PubMed] [Google Scholar]
  49. Tsao P. S., Theilmeier G., Singer A. H., Leung L. L., Cooke J. P. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb. 1994 Oct;14(10):1529–1533. doi: 10.1161/01.atv.14.10.1529. [DOI] [PubMed] [Google Scholar]
  50. Tsikas D., Böger R. H., Bode-Böger S. M., Gutzki F. M., Frölich J. C. Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. J Chromatogr B Biomed Appl. 1994 Nov 18;661(2):185–191. doi: 10.1016/0378-4347(94)00374-2. [DOI] [PubMed] [Google Scholar]
  51. Tsukahara H., Gordienko D. V., Tonshoff B., Gelato M. C., Goligorsky M. S. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994 Feb;45(2):598–604. doi: 10.1038/ki.1994.78. [DOI] [PubMed] [Google Scholar]
  52. Uehara Y., Koga M., Takahashi M. Determination of cardiac output by echocardiography. J Vet Med Sci. 1995 Jun;57(3):401–407. doi: 10.1292/jvms.57.401. [DOI] [PubMed] [Google Scholar]
  53. Wennmalm A., Benthin G., Edlund A., Jungersten L., Kieler-Jensen N., Lundin S., Westfelt U. N., Petersson A. S., Waagstein F. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ Res. 1993 Dec;73(6):1121–1127. doi: 10.1161/01.res.73.6.1121. [DOI] [PubMed] [Google Scholar]
  54. Whitehead H. M., Boreham C., McIlrath E. M., Sheridan B., Kennedy L., Atkinson A. B., Hadden D. R. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 1992 Jan;36(1):45–52. doi: 10.1111/j.1365-2265.1992.tb02901.x. [DOI] [PubMed] [Google Scholar]
  55. Wu H. Y., Jeng Y. Y., Yue C. J., Chyu K. Y., Hsueh W. A., Chan T. M. Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring. Diabetes. 1994 Aug;43(8):1027–1032. doi: 10.2337/diab.43.8.1027. [DOI] [PubMed] [Google Scholar]
  56. Wüster C., Slenczka E., Ziegler R. Erhöhte Prävalenz von Osteoporose und Arteriosklerose bei konventionell substituierter Hypophysenvorderlappeninsuffizienz: Bedarf einer zusätzlichen Wachstumshormonsubstitution? Klin Wochenschr. 1991 Oct 18;69(16):769–773. doi: 10.1007/BF01797616. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES